Another mixed muscarinic/σ1R agonist, ANAVEX2-73, was able to mitigate Aβ25–35-induced tau phosphorylation and Aβ1–42 seeding in mice (Lahmy et al., 2013) and may help to preserve cognition in preliminary clinical trials clinical studies with AD patients (Macfarlane et al., 2016). This evidence concerns the gene MAPT and Alzheimer disease.